NVO•benzinga•
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
Summary
Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on October 31, 2024 by benzinga